The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Improvements and remaining challenges in treating R/R MCL after failure of BTK inhibitors
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how CAR-T therapies and bispecific antibodies have overcome the challenge of treating patients with mantle cell lymphoma (MCL) who fail treatment with BTK inhibitors. Prof. Wang highlights the remaining unmet need of patients who subsequently fail immunotherapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
